For example, detected by Cobas EGFR mutation test v2, a digital PCR assay approved by FDA, non-small-cell lung cancer patients with EGFR exon 19 deletion or exon 21 L858R mutation can be treated by EGFR tyrosine kinase inhibitor erlotinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.